Tocilizumab a ' First Choice ' for PHID Syndrome Tocilizumab a ' First Choice ' for PHID Syndrome
Tocilizumab should be the “ first choice ” for treatment of the autoinflammatory and cutaneous manifestations of pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) syndrome, say clinicians from the United Kingdom.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Pediatrics News Source Type: news
More News: Actemra | Diabetes | Diabetes Mellitus | Endocrinology | Health | Hypertrichosis | Insulin | Pediatrics | UK Health